This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

PharmaPoint: Osteoporosis - Current And Future Players

NEW YORK, May 13, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Osteoporosis - Current and Future Players http://www.reportlinker.com/p01171138/PharmaPoint-Osteoporosis---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=PathologyPharmaPoint: Osteoporosis - Current and Future Players

SummaryOsteoporosis is caused by the gradual weakening of the bones due to abnormal osteocyte function, which occurs as a result of hormonal fluctuations, vitamin deficiency, or aging, and leads to reduced mobility and/or bone fractures.GlobalData has released its pharma report, "PharmaPoint: Osteoporosis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Osteoporosis Market. The report identifies and analyses the key companies shaping and driving the global Osteoporosis market. The report provides insight into the competitive Osteoporosis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding weekends).

Scope- Investigation of current and future market competition for Osteoporosis. - Competitor assessment. - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL)

Reasons to buy- Gain a high level view of the trends shaping and driving the Osteoporosis market. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape - Create an effective counter-strategy to gain a competitive advantage against those currently in the market

Table of Contents1 Table of Contents 41.1 List of Tables 61.2 List of Figures 62 Introduction 72.1 Catalyst 72.2 Related Reports 73 Market Outlook 103.1 Global Markets 103.1.1 Forecast 103.1.2 Drivers and Barriers – Global Issues 134 Current and Future Players 154.1 Overview 154.2 Trends in Corporate Strategy 164.3 Company Profiles 174.3.1 Amgen 174.3.2 Merck 194.3.3 Eli Lilly 224.3.4 Pfizer 254.3.5 Radius Health 275 Appendix 305.1 Bibliography 305.2 Abbreviations 315.3 Methodology 325.4 Forecasting Methodology 325.4.1 Diagnosed Osteoporosis Patients 325.4.2 Percent Drug-Treated Patients 325.4.3 Drugs Included in Each Therapeutic Class 335.4.4 Launch and Patent Expiry Dates 335.4.5 General Pricing Assumptions 345.4.6 Individual Drug Assumptions 345.4.7 Generic Erosion 385.4.8 Pricing of Pipeline Agents 395.5 Physicians and Specialists Included in this Study 405.5.1 About the Authors 415.5.2 Global Head of Healthcare 425.6 About GlobalData 435.7 Contact Us 435.8 Disclaimer 43

List of TablesTable 1: Global Sales Forecasts ($m) for Osteoporosis, 2012-2022 11Table 2: Osteoporosis Market – Drivers and Barriers, 2012–2022 13Table 3: Key Companies in the Osteoporosis Market, 2012 15Table 4: Amgen's Osteoporosis Therapy Portfolio Assessment, 2012 18Table 5: Amgen SWOT Analysis, 2012 18Table 6: Merck's Osteoporosis Therapy Portfolio Assessment, 2012 20Table 7: Merck SWOT Analysis, 2012 21Table 8: Eli Lilly's Osteoporosis Therapy Portfolio Assessment, 2012 23Table 9: Eli Lilly SWOT Analysis, 2012 23Table 10: Pfizer's Osteoporosis Therapy Portfolio Assessment, 2012 25Table 11: Pfizer SWOT Analysis, 2012 26Table 12: Radius Health's Osteoporosis Therapy Portfolio Assessment, 2012 28Table 13: Radius Health SWOT Analysis, 2012 28Table 14: Key Launch Dates 33Table 15: Key Patent Expiries 33Table 16: Number of High-Prescribing Physicians Surveyed 40

List of FiguresFigure 1: Global Sales for Osteoporosis by Region, 2012–2022 12Figure 2: Company Portfolio Gap Analysis in Osteoporosis, 2012–2022 16

To order this report: Pathology Industry: PharmaPoint: Osteoporosis - Current and Future Players__________________________

Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,824.64 +9.70 0.05%
S&P 500 2,070.96 +3.93 0.19%
NASDAQ 4,782.7580 +24.5060 0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs